Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CEP63 antisense RNA 1 (CEP63-AS1) is a long non-coding RNA (lncRNA) gene located antisense to the CEP63 locus. It does not encode a protein. Emerging studies suggest that some antisense lncRNAs can regulate the expression of their sense (protein-coding) gene counterpart, potentially through transcriptional interference, chromatin remodeling, or RNA-RNA interactions. While the precise biological function and clinical significance of CEP63-AS1 remain undetermined, some recent research implicates certain antisense lncRNAs in cancer, including possible roles in oncogenesis or as prognostic biomarkers. However, there are no validated drug interactions, established disease biomarkers, or recognized safety concerns linked to CEP63-AS1 at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CEP63 antisense RNA 1 (CEP63-AS1).